$AMBS NEW YORK, June 07, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire – Amarantus Bioscience Holdings, Inc. (OTC Pink:AMBS) (the "Company," or AMBS), a US-based, JLABS-alumnus biotechnology holding company developing first-in-class orphan neurologic, regenerative medicine and ophthalmic therapies and diagnostics through its subsidiaries, today provided an update to the marketplace on its capital formation plans for its wholly-owned subsidiary Elto Pharma, Inc.

https://finance.yahoo.com/news/amarantus-prov...46167.html